Similar companies
Did Royalty Pharma Beat Earnings?
Royalty Pharma (RPRX) reported Q2 '26 revenue of $674M, up 16.5% year-over-year, with reported EPS of $1.32. That topped the $1.27 analyst estimate by 3.9% — an earnings beat.
AltIndex tracks earnings alongside 25+ alternative data signals that can move ahead of the report — Royalty Pharma’s job postings, web traffic, and employee business outlook. See the full RPRX stock analysis or the earnings calendar for upcoming reports.
RPRX Earnings Surprise History (EPS vs. Estimate)
| Quarter | Estimated EPS | Reported EPS | Surprise |
|---|---|---|---|
| Q2 '26 | $1.27 | $1.32 | Beat +3.9% |
| Q1 '26 | $1.18 | $1.30 | Beat +10.2% |
| Q4 '25 | $1.33 | $1.47 | Beat +10.5% |
| Q3 '25 | $1.11 | $1.17 | Beat +5.4% |
| Q2 '25 | $1.03 | $1.14 | Beat +10.7% |
| Q1 '25 | $0.95 | $1.06 | Beat +11.6% |
Royalty Pharma Quarterly Financial Trends
| Metric | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 565M | 594M | 568M | 579M | 609M | 622M | 631M | 674M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 99.8% | 60.2% |
| Operating margin | 130.2% | 60.9% | 94.0% | 36.3% | 70.1% | 62.4% | 100.3% | 19.7% |
| Net income | 544M | 208M | 238M | 30M | 288M | 214M | 295M | 18M |
| Net margin | 96.3% | 35.1% | 41.9% | 5.2% | 47.3% | 34.4% | 46.8% | 2.7% |
| EPS | $1.04 | $1.15 | $1.06 | $1.14 | $1.17 | $1.47 | $1.30 | $1.32 |
Royalty Pharma Earnings Trend Analysis
Over the eight quarters from Q3 '24 to Q2 '26, Royalty Pharma’s quarterly revenue moved from $565M to $674M. Net margin compressed from 96.3% to 2.7%, against a 60.2% gross margin in the most recent quarter — a read on whether revenue growth is translating into profit. Royalty Pharma has beaten Wall Street EPS estimates in 8 of its last 8 reported quarters.
When Is Royalty Pharma’s Next Earnings Date?
Royalty Pharma reports earnings on a quarterly schedule. Its most recent report covered Q2 '26. For the confirmed upcoming date — and every other company reporting soon — see the RPRX earnings calendar.
Frequently Asked Questions: Royalty Pharma Earnings
Royalty Pharma's next earnings date has not been confirmed yet. See the earnings calendar for all upcoming reports.
Royalty Pharma reported Q2 '26 EPS of $1.32 on revenue of $674M (+16.5% YoY). Royalty Pharma beat estimates, reporting $1.32 vs. the $1.27 estimate.
Royalty Pharma reported Q2 '26 revenue of $674M, up 16.5% from the same quarter a year earlier.
Signals like job postings, web traffic, and employee sentiment reflect business activity in real time and can move before quarterly results are reported. AltIndex combines them with 25+ others in the RPRX AI Score.
